SCHEMBL3045642

SCHEMBL3045642

Nc1cc(F)c(N2CCSCC2)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.44
ALDH1A1 P00352 5/20 0.42
ALOX15 P16050 1/20 0.42
MAPK10 P53779 1/20 0.42
HSD17B10 Q99714 1/20 0.42
LGMN Q99538 2/20 0.42
MAPT P10636 5/20 0.34
LMNA P02545 2/20 0.34
MAPK1 P28482 2/20 0.34
GFER P55789 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
KDM4E B2RXH2 1/20 0.33
MAOA P21397 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
AR P10275 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
POLB P06746 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23833818 0.98 GAA (0.43) GAAALDH1A1ALOX15MAPK10HSD17B10
SCHEMBL18396824 0.89 GAA (0.36) GAAALDH1A1ALOX15MAPK10HSD17B10
SCHEMBL238377 0.79 ALDH1A1 (0.43) GAAALDH1A1ALOX15HSD17B10MAPT
SCHEMBL28980419 0.78 MAPT (0.35) ALDH1A1MAPTLMNAMAPK1GFER
SCHEMBL22689488 0.77
SCHEMBL1354385 0.76 MAOA (0.50) GAAALDH1A1LGMNMAPTLMNA
SCHEMBL17144408 0.76 MAPT (0.51) GAAALDH1A1MAPTMAPK1GFER
SCHEMBL22171244 0.76 ALDH1A1 (0.51) GAAALDH1A1MAPTLMNAKDM4E
SCHEMBL239103 0.76 ALDH1A1 (0.45) GAAALDH1A1HSD17B10MAPTLMNA
SCHEMBL240318 0.76 SSTR2 (0.38) GAAALDH1A1MAPTLMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121058-B1 OXAZOLIDINONE COMPOUND AND ITS USE THEREOF AS AN ANTIBACTERIAL AGENT MERCK SHARP & DOHME LLC (US) 2026-02-18 EP disclosed
US-12435077-B2 Oxazolidinone compound and methods of use thereof as an antibacterial agent MERCK SHARP & DOHME LLC (US) 2025-10-07 US disclosed
US-20240208958-A1 OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT MERCK SHARP & DOHME LLC (US) 2024-06-27 US disclosed
US-20240208958-A1 OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT MERCK SHARP & DOHME LLC (US) 2024-06-27 US disclosed
US-20240208958-A1 OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT MERCK SHARP & DOHME LLC (US) 2024-06-27 US disclosed
WO-2024035618-A1 PROCESSES FOR PREPARING OXAZOLIDINONE COMPOUNDS MERCK SHARP & DOHME LLC (US) 2024-02-15 WO disclosed
EP-4121058-A1 OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT Merck Sharp & Dohme LLC (US) 2023-01-25 EP disclosed
WO-2021188606-A1 OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT MERCK SHARP & DOHME CORP. (US) 2021-09-23 WO disclosed
WO-2021188606-A1 OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT MERCK SHARP & DOHME CORP. (US) 2021-09-23 WO disclosed
US-7645781-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER INC (US) 2010-01-12 US disclosed
US-20050209223-A1 Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED 2005-09-22 US disclosed
US-6919329-B2 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY (US) 2005-07-19 US disclosed
US-6914058-B2 1-(p-(thiomorpholino)phenyl)-1,2,3-triazole derivatives DR. REDDY'S LABORATORIES, LIMITED (IN) 2005-07-05 US disclosed
US-20050113347-A1 NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DR. REDDY'S LABORATORIES LIMITED 2005-05-26 US disclosed
EP-1478629-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2004-11-24 EP disclosed
EP-1467977-A1 NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. Dr. Reddy's Laboratories Ltd. (IN) 2004-10-20 EP disclosed
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US disclosed
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-03-04 US disclosed
WO-2003072553-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2003-09-04 WO disclosed
WO-2003059894-A1 NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. DR.REDDY'S LABORATORIES LTD. (IN) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435077-B2 Oxazolidinone compound and methods of use thereof as an antibacterial agent OXA1L, IL17A, TBCD GAA 674/4885ALDH1A1 446/4885ALOX15 1431/4885
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 GAA 2636/4885ALDH1A1 956/4885ALOX15 3786/4885
US-20240208958-A1 OXAZOLIDINONE COMPOUND AND METHODS OF USE THEREOF AS AN ANTIBACTERIAL AGENT OXA1L, IL17A, TBCD GAA 674/4885ALDH1A1 446/4885ALOX15 1431/4885
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 GAA 2636/4885ALDH1A1 956/4885ALOX15 3786/4885
US-20050209223-A1 Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them CYP3A4, CYP3A43, CYP3A5 GAA 747/4885ALDH1A1 2745/4885ALOX15 3049/4885
US-20050113347-A1 NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CYP3A4, CYP3A43, CYP3A5 GAA 747/4885ALDH1A1 2745/4885ALOX15 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.